FDA Speeds Up Cancer Drug Approvals with New Testing Tricks
Published Date: 1/21/2026
Notice
Summary
The FDA is rolling out new draft guidance to help drug makers use special tests called minimal residual disease (MRD) and complete response (CR) to speed up approval of multiple myeloma treatments. This means patients with this blood cancer could get access to promising drugs faster. Industry folks should send their feedback by March 23, 2026, so the FDA can finalize the rules and keep innovation moving without unnecessary delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Faster access to myeloma treatments
If you have multiple myeloma, the FDA's draft guidance says sponsors may use minimal residual disease (MRD) negativity and complete response (CR) as primary endpoints to support accelerated approval. That could allow promising multiple myeloma drugs to reach patients faster than traditional endpoints.
Clear trial road map for drug sponsors
If you are a drug sponsor, the FDA's draft guidance provides recommendations on using MRD and CR as primary endpoints to support accelerated approval and includes trial design, statistical, and assay considerations. The Agency requests comments on the draft by March 23, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in